Alta Bates Medical Group; Analysis of Proposed Consent Order to Aid Public Comment, 28246-28248 [E9-13956]
Download as PDF
28246
Federal Register / Vol. 74, No. 113 / Monday, June 15, 2009 / Notices
help affected consumers uninstall the
Application.
Part III of the proposed order requires
that Respondent, to the extent it has not
already done so, cease collecting any
data transmitted by any previously
installed Tracking Application and to
destroy any previously collected data.
Parts IV through VII of the proposed
order require Respondent: to keep
copies of relevant consumer complaints
and inquiries, documents demonstrating
order compliance, and advertisements
and other documents relating to
dissemination of any Tracking
Application; to provide copies of the
order to certain of their personnel; to
notify the Commission of changes in
corporate structure that might affect
compliance obligations under the order;
and to file compliance reports with the
Commission. Part VIII provides that the
order will terminate after twenty (20)
years, with certain exceptions.
The purpose of this analysis is to
facilitate public comment on the
proposed order, and it is not intended
to constitute an official interpretation of
the agreement and proposed order or to
modify in any way their terms.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. E9–13955 Filed 6–12–09: 8:45 am]
BILLING CODE: 6750–01–S
FEDERAL TRADE COMMISSION
[File No. 051 0260]
Alta Bates Medical Group; Analysis of
Proposed Consent Order to Aid Public
Comment
Federal Trade Commission.
Proposed Consent Agreement.
AGENCY:
pwalker on PROD1PC71 with NOTICES
ACTION:
SUMMARY: The consent agreement in this
matter settles alleged violations of
federal law prohibiting unfair or
deceptive acts or practices or unfair
methods of competition. The attached
Analysis to Aid Public Comment
describes both the allegations in the
complaint and the terms of the consent
order—embodied in the consent
agreement—that would settle these
allegations.
DATES: Comments must be received on
or before July 6, 2009.
ADDRESSES: Interested parties are
invited to submit written comments
electronically or in paper form.
Comments should refer to‘‘Alta Bates,
File No. 051 0260’’ to facilitate the
organization of comments. Please note
that your comment—including your
name and your state—will be placed on
VerDate Nov<24>2008
16:47 Jun 12, 2009
Jkt 217001
the public record of this proceeding,
including on the publicly accessible
FTC website, at (https://www.ftc.gov/os/
publiccomments.shtm).
Because comments will be made
public, they should not include any
sensitive personal information, such as
an individual’s Social Security Number;
date of birth; driver’s license number or
other state identification number, or
foreign country equivalent; passport
number; financial account number; or
credit or debit card number. Comments
also should not include any sensitive
health information, such as medical
records or other individually
identifiable health information. In
addition, comments should not include
any ‘‘[t]rade secret or any commercial or
financial information which is obtained
from any person and which is privileged
or confidential. . . .,’’ as provided in
Section 6(f) of the FTC Act, 15 U.S.C.
46(f), and Commission Rule 4.10(a)(2),
16 CFR 4.10(a)(2). Comments containing
material for which confidential
treatment is requested must be filed in
paper form, must be clearly labeled
‘‘Confidential,’’ and must comply with
FTC Rule 4.9(c), 16 CFR 4.9(c).1
Because paper mail addressed to the
FTC is subject to delay due to
heightened security screening, please
consider submitting your comments in
electronic form. Comments filed in
electronic form should be submitted by
using the following weblink: (https://
secure.commentworks.com/ftcaltabates) (and following the
instructions on the web-based form). To
ensure that the Commission considers
an electronic comment, you must file it
on the web-based form at the weblink:
(https://secure.commentworks.com/ftcaltabates). If this Notice appears at
(https://www.regulations.gov/search/
index.jsp), you may also file an
electronic comment through that
website. The Commission will consider
all comments that regulations.gov
forwards to it. You may also visit the
FTC website at https://www.ftc.gov/ to
read the Notice and the news release
describing it.
A comment filed in paper form
should include the ‘‘Alta Bates, File No.
051 0260‘‘ reference both in the text and
on the envelope, and should be mailed
or delivered to the following address:
Federal Trade Commission, Office of the
1 The comment must be accompanied by an
explicit request for confidential treatment,
including the factual and legal basis for the request,
and must identify the specific portions of the
comment to be withheld from the public record.
The request will be granted or denied by the
Commission’s General Counsel, consistent with
applicable law and the public interest. See FTC
Rule 4.9(c), 16 CFR 4.9(c).
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Secretary, Room H–135 (Annex D), 600
Pennsylvania Avenue, NW, Washington,
DC 20580. The FTC is requesting that
any comment filed in paper form be sent
by courier or overnight service, if
possible, because U.S. postal mail in the
Washington area and at the Commission
is subject to delay due to heightened
security precautions.
The Federal Trade Commission Act
(‘‘FTC Act’’) and other laws the
Commission administers permit the
collection of public comments to
consider and use in this proceeding as
appropriate. The Commission will
consider all timely and responsive
public comments that it receives,
whether filed in paper or electronic
form. Comments received will be
available to the public on the FTC
website, to the extent practicable, at
(https://www.ftc.gov/os/
publiccomments.shtm). As a matter of
discretion, the Commission makes every
effort to remove home contact
information for individuals from the
public comments it receives before
placing those comments on the FTC
website. More information, including
routine uses permitted by the Privacy
Act, may be found in the FTC’s privacy
policy, at (https://www.ftc.gov/ftc/
privacy.shtm).
FOR FURTHER INFORMATION CONTACT:
Sylvai Kundig or Linda Badger, FTC
Western Region, San Francisco, 600
Pennsylvania Avenue, NW, Washington,
D.C. 20580, (415) 848–5100.
SUPPLEMENTARY INFORMATION: Pursuant
to section 6(f) of the Federal Trade
Commission Act, 38 Stat. 721, 15 U.S.C.
46(f), and § 2.34 the Commission Rules
of Practice, 16 CFR 2.34, notice is
hereby given that the above-captioned
consent agreement containing a consent
order to cease and desist, having been
filed with and accepted, subject to final
approval, by the Commission, has been
placed on the public record for a period
of thirty (30) days. The following
Analysis to Aid Public Comment
describes the terms of the consent
agreement, and the allegations in the
complaint. An electronic copy of the
full text of the consent agreement
package can be obtained from the FTC
Home Page (for June 4, 2009), on the
World Wide Web, at (https://
www.ftc.gov/os/actions.shtm). A paper
copy can be obtained from the FTC
Public Reference Room, Room 130-H,
600 Pennsylvania Avenue, NW,
Washington, D.C. 20580, either in
person or by calling (202) 326—2222.
Public comments are invited, and may
be filed with the Commission in either
paper or electronic form. All comments
should be filed as prescribed in the
E:\FR\FM\15JNN1.SGM
15JNN1
Federal Register / Vol. 74, No. 113 / Monday, June 15, 2009 / Notices
section above, and must be
received on or before the date specified
in the DATES section.
ADDRESSES
pwalker on PROD1PC71 with NOTICES
Analysis of Agreement Containing
Consent Order to Aid Public Comment
The Federal Trade Commission has
accepted, subject to final approval, an
agreement containing a proposed
Consent Order with Alta Bates Medical
Group, Inc., (‘‘ABMG’’ or
‘‘Respondent’’). The agreement settles
charges that ABMG violated Section 5 of
the Federal Trade Commission Act, 15
U.S.C. § 45, by fixing prices charged to
those offering coverage for health care
services (‘‘payors’’) in the Berkeley and
Oakland, California, area and refusing to
deal with payors except on a
collectively determined basis. The
proposed Consent Order has been
placed on the public record for 30 days
to receive comments from interested
persons. Comments received during this
period will become part of the public
record. After 30 days, the Commission
will review the agreement and the
comments received, and will decide
whether it should withdraw from the
agreement or make the proposed
Consent Order final.
The purpose of this analysis is to
facilitate public comment on the
proposed Consent Order. The analysis is
not intended to constitute an official
interpretation of the agreement and
proposed Consent Order or to modify
their terms in any way. Further, the
proposed Consent Order has been
entered into for settlement purposes
only and does not constitute an
admission by Respondent that it
violated the law or that the facts alleged
in the Complaint (other than
jurisdictional facts) are true.
Alta Bates Medical Group, Inc.
ABMG is a multi-specialty
independent practice association
(‘‘IPA’’) comprised of multiple,
independent medical practices serving
the Berkeley and Oakland, California
area. It has a total of approximately 600
physician members, of which
approximately 200 are devoted to
primary care. Since its formation,
ABMG has negotiated group contracts
with payors under which it receives
capitated (per member per month)
payments. These contracts shift the risk
of patient illness to the IPA by
specifying that the health plan will pay
the IPA a flat monthly fee for each
enrollee, with almost no regard for
patient utilization. This type of
contracting is a form of financial
integration, so for anititrust purposes,
the IPA is treated as a single entity for
purposes of these contract negotiations,
VerDate Nov<24>2008
16:47 Jun 12, 2009
Jkt 217001
and not as a group of competing
physicians. The complaint does not
challenge ABMG’s activities concerning
these contracts.
ABMG, however, also contracts on
behalf of its member physicians with
health plans to provide fee-for-service
medical care. Under these arrangements,
the payor compensates physicians or
group practices for services actually
rendered pursuant to agreed-upon fee
schedules. In the absence of financial
risk-sharing or clinical integration on
the part of providers, the IPA members
are competitors for purposes of antitrust
analysis. It is ABMG’s negotiation of feefor-service contracts that is the subject
of the allegations in the Commission’s
Complaint.
The Complaint
Since at least 2001, ABMG, acting as
a combination of its physician members,
and in conspiracy with its members, has
acted to restrain competition with
respect to fee-for-service contracts by,
among other things, facilitating, entering
into, and implementing agreements,
express or implied, to fix the prices and
other terms at which they would
contract with payors; to engage in
collective negotiations over terms and
conditions of dealing with payors; and
to have ABMG members refrain from
negotiating individually with payors or
contracting on terms other than those
approved by ABMG. This type of
collective conduct by competitors is
inherently suspect under the antitrust
laws.
At times, however, IPAs will act as a
conduit between physician members
and health plans regarding fee-forservice contracts to facilitate the
contracting process. Under this model,
the IPA merely acts as a messenger and
does not negotiate the terms of the
contract.
Although claiming to employ a lawful
messenger arrangement, ABMG, on
behalf of its physician members, instead
orchestrated collective negotiations for
fee-for-service contracts. Specific acts by
ABMG that are alleged in the complaint
are: making proposals and counterproposals, as well as accepting or
rejecting offers, without consulting with
its individual physician members
regarding the prices they unilaterally
would accept, and without transmitting
the payors’ offers to its individual
physician members until ABMG had
approved the negotiated prices.
The complaint also alleged a
concerted refusal to deal intended to
impede competition by one of ABMG’s
major competitors, the Permanente
Medical Group, which provides
physician services exclusively to Kaiser
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
28247
Foundation Health Plan, Inc. In 2006,
Kaiser2 was expanding a fee-for-service
product, under which covered
individuals could access physician
services through a national third-party
network that included ABMG
physicians. This expansion by Kaiser
threatened ultimately to reduce ABMG’s
business under its capitated contracts,
by giving Kaiser the ability to offer
employers both a capitated and fee-forservice health plan option. To impede
this expansion, ABMG attempted a
concerted refusal to serve Kaiser fee-forservice enrollees. Although ABMG’s
refusal to deal was ultimately
unsuccessful, the sole purpose of this
action was to impede competition in the
provision of physician services in and
around Berkeley and Oakland,
California.
ABMG did not engage in any activity
that might justify collective agreements
on the prices its members would accept
for their services. For example, the
physicians in ABMG have not clinically
or financially integrated their practices
to create efficiencies sufficient to justify
their acts and practices. As a
consequence, the Respondent’s actions
have restrained price and other forms of
competition among physicians in the
Berkeley and Oakland, California, area
and thereby harmed consumers
(including health plans, employers, and
individual consumers) by increasing the
prices for physician services.
The Proposed Consent Order
The proposed Consent Order is
designed to prevent the continuance
and recurrence of the illegal conduct
alleged in the complaint while it allows
ABMG to engage in legitimate, joint
conduct. The proposed Consent Order
does not affect ABMG’s activities in
contracting with the payors on a
capitated basis.
Paragraph II.A prohibits Respondent
from entering into or facilitating any
agreement between or among any health
care providers: (1) to negotiate on behalf
of any physician with any payor; (2) to
refuse to deal, or threaten to refuse to
deal with any payor; (3) regarding any
term, condition, or requirement upon
which any physician deals, or is willing
to deal, with any payor, including, but
not limited to price terms; or (4) not to
deal individually with any payor, or not
to deal with any payor other than
through ABMG.
The other parts of Paragraph II
reinforce these general prohibitions.
2 Kaiser is a trade name for an association of three
entities: Kaiser Foundation Health Plan, Inc.; Kaiser
Foundation Hospitals; and the Permanente Medical
Groups.
E:\FR\FM\15JNN1.SGM
15JNN1
28248
Federal Register / Vol. 74, No. 113 / Monday, June 15, 2009 / Notices
Paragraph II.B prohibits the Respondent
from facilitating exchanges of
information between health care
providers concerning whether, or on
what terms, to contract with a payor.
Paragraph II.C bars attempts to engage in
any action prohibited by Paragraph II.A
or II.B, and Paragraph II.D proscribes
encouraging, suggesting, advising,
pressuring, inducing, or attempting to
induce any person to engage in any
action that would be prohibited by
Paragraphs II.A through II.C.
As in other Commission orders
addressing health care providers’
collective bargaining with health care
payors, certain kinds of agreements are
excluded from the general bar on joint
negotiations. Paragraph II does not
preclude ABMG from engaging in
conduct that is reasonably necessary to
form or participate in legitimate
‘‘qualified risk-sharing’’ or ‘‘qualified
clinically-integrated’’ joint
arrangements, as defined in the
proposed Consent Order. Also,
Paragraph II would not bar agreements
that only involve physicians who are
part of the same medical group practice,
defined in Paragraph I.B, because it is
intended to reach agreements between
and among independent competitors.
Paragraphs III through VI require
ABMG to notify the Commission before
it initiates certain contacts regarding
contracts with payors. Paragraphs III
and IV apply to arrangements under
which ABMG would be acting as a
messenger on behalf of its member
physicians. Paragraphs V and VI discuss
arrangements under which ABMG plans
to achieve financial or clinical
integration.
Paragraph VII.A requires ABMG to
send a copy of the Complaint and
Consent Order to its physician
members, its management and staff, and
any payors who communicated with
ABMG, or with whom ABMG
communicated, with regard to any
interest in contracting for physician
services, at any time since January 1,
2001.
Paragraph VII.B requires ABMG to
terminate, without penalty, pre-existing
payer contracts that it had entered into
since 2001, at the earlier of (1) receipt
by ABMG of a written request for
termination by the payer; or (2) the
termination date, renewal date, or
anniversary date of the contract. This
provision is intended to eliminate the
effects of ABMG’s illegal collective
behavior. The payer can delay the
termination for up to one year by
making a written request to ABMG.
Paragraph VII.D contains three-year
notification provisions relating to future
contact with physicians, payors,
management and staff. This provision
requires ABMG to distribute a copy of
the Complaint and Consent Order to
each physician who begins participating
in ABMG; each payor who contacts
ABMG regarding the provision of
physician services; and each person
who becomes an officer, director,
manager, or employee for five years after
the date on which the Consent Order
becomes final. In addition, Paragraph
VII.D requires ABMG to publish a copy
of the Complaint and Consent Order,
annually, in any official publication that
it sends to its participating physicians.
Paragraphs VII.E and VIII–IX impose
various obligations on ABMG to report
or to provide access to information to
the Commission to facilitate monitoring
its compliance with the Consent Order.
Pursuant to Paragraph X, the
proposed Consent Order will expire in
20 years from the date it is issued.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. E9–13956 Filed 6–12–09: 8:45 am]
BILLING CODE: 6750–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Comment Request
Title: Low Income Home Energy
Assistance Program LIHEAP Leveraging
Report.
OMB No.: 0970–0121.
Description: The LIHEAP leveraging
incentive program rewards LIHEAP
grantees that have leveraged non-federal
home energy resources for low-income
households. The LIHEAP leveraging
report is the application for leveraging
incentive funds that these LIHEAP
grantees submit to the Department of
Health and Human Services for each
fiscal year in which they leverage
countable resources. Participation in the
leveraging incentive program is
voluntary and is described at 45 CFR
96.87. The LIHEAP leveraging report
obtains information on the resources
leveraged by LIHEAP grantees each
fiscal year (as cash, discounts, waivers,
and in-kind); the benefits provided to
low-income households by these
resources (for example, as fuel and
payments for fuel, as home heating and
cooling equipment, and as
weatherization materials and
installation); and the fair market value
of these resources/benefits.
HHS needs this information in order
to carry out statutory requirements for
administering the LIHEAP leveraging
incentive program, to determine
countability and valuation of grantees
leveraged non-federal home energy
resources, and to determine grantees
shares of leveraging incentive funds.
HHS proposes to request a three-year
extension of OMB approval for the
currently approved LIHEAP leveraging
report information collection.
Respondents: State, Local or Tribal
Governments.
ANNUAL BURDEN ESTIMATES
Number of
respondents
Number of
responses per
respondent
Average
burden hours
per response
Total
burden hours
LIHEAP Leveraging Report .....................................................................
pwalker on PROD1PC71 with NOTICES
Instrument
70
1
38
2,660
Estimated Total Annual Burden
Hours: 2,660
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Administration, Office of Information
VerDate Nov<24>2008
16:47 Jun 12, 2009
Jkt 217001
Services, 370 L’Enfant Promenade, SW.,
Washington, DC 20447, Attn: ACF
Reports Clearance Officer. All requests
should be identified by the title of the
information collection. E-mail address:
infocollection@acf.hhs.gov.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
E:\FR\FM\15JNN1.SGM
15JNN1
Agencies
[Federal Register Volume 74, Number 113 (Monday, June 15, 2009)]
[Notices]
[Pages 28246-28248]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-13956]
-----------------------------------------------------------------------
FEDERAL TRADE COMMISSION
[File No. 051 0260]
Alta Bates Medical Group; Analysis of Proposed Consent Order to
Aid Public Comment
AGENCY: Federal Trade Commission.
ACTION: Proposed Consent Agreement.
-----------------------------------------------------------------------
SUMMARY: The consent agreement in this matter settles alleged
violations of federal law prohibiting unfair or deceptive acts or
practices or unfair methods of competition. The attached Analysis to
Aid Public Comment describes both the allegations in the complaint and
the terms of the consent order--embodied in the consent agreement--that
would settle these allegations.
DATES: Comments must be received on or before July 6, 2009.
ADDRESSES: Interested parties are invited to submit written comments
electronically or in paper form. Comments should refer to``Alta Bates,
File No. 051 0260'' to facilitate the organization of comments. Please
note that your comment--including your name and your state--will be
placed on the public record of this proceeding, including on the
publicly accessible FTC website, at (https://www.ftc.gov/os/publiccomments.shtm).
Because comments will be made public, they should not include any
sensitive personal information, such as an individual's Social Security
Number; date of birth; driver's license number or other state
identification number, or foreign country equivalent; passport number;
financial account number; or credit or debit card number. Comments also
should not include any sensitive health information, such as medical
records or other individually identifiable health information. In
addition, comments should not include any ``[t]rade secret or any
commercial or financial information which is obtained from any person
and which is privileged or confidential. . . .,'' as provided in
Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and Commission Rule
4.10(a)(2), 16 CFR 4.10(a)(2). Comments containing material for which
confidential treatment is requested must be filed in paper form, must
be clearly labeled ``Confidential,'' and must comply with FTC Rule
4.9(c), 16 CFR 4.9(c).\1\
---------------------------------------------------------------------------
\1\ The comment must be accompanied by an explicit request for
confidential treatment, including the factual and legal basis for
the request, and must identify the specific portions of the comment
to be withheld from the public record. The request will be granted
or denied by the Commission's General Counsel, consistent with
applicable law and the public interest. See FTC Rule 4.9(c), 16 CFR
4.9(c).
---------------------------------------------------------------------------
Because paper mail addressed to the FTC is subject to delay due to
heightened security screening, please consider submitting your comments
in electronic form. Comments filed in electronic form should be
submitted by using the following weblink: (https://secure.commentworks.com/ftc-altabates) (and following the instructions
on the web-based form). To ensure that the Commission considers an
electronic comment, you must file it on the web-based form at the
weblink: (https://secure.commentworks.com/ftc-altabates). If this
Notice appears at (https://www.regulations.gov/search/index.jsp), you
may also file an electronic comment through that website. The
Commission will consider all comments that regulations.gov forwards to
it. You may also visit the FTC website at https://www.ftc.gov/ to read
the Notice and the news release describing it.
A comment filed in paper form should include the ``Alta Bates, File
No. 051 0260`` reference both in the text and on the envelope, and
should be mailed or delivered to the following address: Federal Trade
Commission, Office of the Secretary, Room H-135 (Annex D), 600
Pennsylvania Avenue, NW, Washington, DC 20580. The FTC is requesting
that any comment filed in paper form be sent by courier or overnight
service, if possible, because U.S. postal mail in the Washington area
and at the Commission is subject to delay due to heightened security
precautions.
The Federal Trade Commission Act (``FTC Act'') and other laws the
Commission administers permit the collection of public comments to
consider and use in this proceeding as appropriate. The Commission will
consider all timely and responsive public comments that it receives,
whether filed in paper or electronic form. Comments received will be
available to the public on the FTC website, to the extent practicable,
at (https://www.ftc.gov/os/publiccomments.shtm). As a matter of
discretion, the Commission makes every effort to remove home contact
information for individuals from the public comments it receives before
placing those comments on the FTC website. More information, including
routine uses permitted by the Privacy Act, may be found in the FTC's
privacy policy, at (https://www.ftc.gov/ftc/privacy.shtm).
FOR FURTHER INFORMATION CONTACT: Sylvai Kundig or Linda Badger, FTC
Western Region, San Francisco, 600 Pennsylvania Avenue, NW, Washington,
D.C. 20580, (415) 848-5100.
SUPPLEMENTARY INFORMATION: Pursuant to section 6(f) of the Federal
Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46(f), and Sec. 2.34 the
Commission Rules of Practice, 16 CFR 2.34, notice is hereby given that
the above-captioned consent agreement containing a consent order to
cease and desist, having been filed with and accepted, subject to final
approval, by the Commission, has been placed on the public record for a
period of thirty (30) days. The following Analysis to Aid Public
Comment describes the terms of the consent agreement, and the
allegations in the complaint. An electronic copy of the full text of
the consent agreement package can be obtained from the FTC Home Page
(for June 4, 2009), on the World Wide Web, at (https://www.ftc.gov/os/actions.shtm). A paper copy can be obtained from the FTC Public
Reference Room, Room 130-H, 600 Pennsylvania Avenue, NW, Washington,
D.C. 20580, either in person or by calling (202) 326--2222.
Public comments are invited, and may be filed with the Commission
in either paper or electronic form. All comments should be filed as
prescribed in the
[[Page 28247]]
ADDRESSES section above, and must be received on or before the date
specified in the DATES section.
Analysis of Agreement Containing Consent Order to Aid Public Comment
The Federal Trade Commission has accepted, subject to final
approval, an agreement containing a proposed Consent Order with Alta
Bates Medical Group, Inc., (``ABMG'' or ``Respondent''). The agreement
settles charges that ABMG violated Section 5 of the Federal Trade
Commission Act, 15 U.S.C. Sec. 45, by fixing prices charged to those
offering coverage for health care services (``payors'') in the Berkeley
and Oakland, California, area and refusing to deal with payors except
on a collectively determined basis. The proposed Consent Order has been
placed on the public record for 30 days to receive comments from
interested persons. Comments received during this period will become
part of the public record. After 30 days, the Commission will review
the agreement and the comments received, and will decide whether it
should withdraw from the agreement or make the proposed Consent Order
final.
The purpose of this analysis is to facilitate public comment on the
proposed Consent Order. The analysis is not intended to constitute an
official interpretation of the agreement and proposed Consent Order or
to modify their terms in any way. Further, the proposed Consent Order
has been entered into for settlement purposes only and does not
constitute an admission by Respondent that it violated the law or that
the facts alleged in the Complaint (other than jurisdictional facts)
are true.
Alta Bates Medical Group, Inc.
ABMG is a multi-specialty independent practice association
(``IPA'') comprised of multiple, independent medical practices serving
the Berkeley and Oakland, California area. It has a total of
approximately 600 physician members, of which approximately 200 are
devoted to primary care. Since its formation, ABMG has negotiated group
contracts with payors under which it receives capitated (per member per
month) payments. These contracts shift the risk of patient illness to
the IPA by specifying that the health plan will pay the IPA a flat
monthly fee for each enrollee, with almost no regard for patient
utilization. This type of contracting is a form of financial
integration, so for anititrust purposes, the IPA is treated as a single
entity for purposes of these contract negotiations, and not as a group
of competing physicians. The complaint does not challenge ABMG's
activities concerning these contracts.
ABMG, however, also contracts on behalf of its member physicians
with health plans to provide fee-for-service medical care. Under these
arrangements, the payor compensates physicians or group practices for
services actually rendered pursuant to agreed-upon fee schedules. In
the absence of financial risk-sharing or clinical integration on the
part of providers, the IPA members are competitors for purposes of
antitrust analysis. It is ABMG's negotiation of fee-for-service
contracts that is the subject of the allegations in the Commission's
Complaint.
The Complaint
Since at least 2001, ABMG, acting as a combination of its physician
members, and in conspiracy with its members, has acted to restrain
competition with respect to fee-for-service contracts by, among other
things, facilitating, entering into, and implementing agreements,
express or implied, to fix the prices and other terms at which they
would contract with payors; to engage in collective negotiations over
terms and conditions of dealing with payors; and to have ABMG members
refrain from negotiating individually with payors or contracting on
terms other than those approved by ABMG. This type of collective
conduct by competitors is inherently suspect under the antitrust laws.
At times, however, IPAs will act as a conduit between physician
members and health plans regarding fee-for-service contracts to
facilitate the contracting process. Under this model, the IPA merely
acts as a messenger and does not negotiate the terms of the contract.
Although claiming to employ a lawful messenger arrangement, ABMG,
on behalf of its physician members, instead orchestrated collective
negotiations for fee-for-service contracts. Specific acts by ABMG that
are alleged in the complaint are: making proposals and counter-
proposals, as well as accepting or rejecting offers, without consulting
with its individual physician members regarding the prices they
unilaterally would accept, and without transmitting the payors' offers
to its individual physician members until ABMG had approved the
negotiated prices.
The complaint also alleged a concerted refusal to deal intended to
impede competition by one of ABMG's major competitors, the Permanente
Medical Group, which provides physician services exclusively to Kaiser
Foundation Health Plan, Inc. In 2006, Kaiser\2\ was expanding a fee-
for-service product, under which covered individuals could access
physician services through a national third-party network that included
ABMG physicians. This expansion by Kaiser threatened ultimately to
reduce ABMG's business under its capitated contracts, by giving Kaiser
the ability to offer employers both a capitated and fee-for-service
health plan option. To impede this expansion, ABMG attempted a
concerted refusal to serve Kaiser fee-for-service enrollees. Although
ABMG's refusal to deal was ultimately unsuccessful, the sole purpose of
this action was to impede competition in the provision of physician
services in and around Berkeley and Oakland, California.
---------------------------------------------------------------------------
\2\ Kaiser is a trade name for an association of three entities:
Kaiser Foundation Health Plan, Inc.; Kaiser Foundation Hospitals;
and the Permanente Medical Groups.
---------------------------------------------------------------------------
ABMG did not engage in any activity that might justify collective
agreements on the prices its members would accept for their services.
For example, the physicians in ABMG have not clinically or financially
integrated their practices to create efficiencies sufficient to justify
their acts and practices. As a consequence, the Respondent's actions
have restrained price and other forms of competition among physicians
in the Berkeley and Oakland, California, area and thereby harmed
consumers (including health plans, employers, and individual consumers)
by increasing the prices for physician services.
The Proposed Consent Order
The proposed Consent Order is designed to prevent the continuance
and recurrence of the illegal conduct alleged in the complaint while it
allows ABMG to engage in legitimate, joint conduct. The proposed
Consent Order does not affect ABMG's activities in contracting with the
payors on a capitated basis.
Paragraph II.A prohibits Respondent from entering into or
facilitating any agreement between or among any health care providers:
(1) to negotiate on behalf of any physician with any payor; (2) to
refuse to deal, or threaten to refuse to deal with any payor; (3)
regarding any term, condition, or requirement upon which any physician
deals, or is willing to deal, with any payor, including, but not
limited to price terms; or (4) not to deal individually with any payor,
or not to deal with any payor other than through ABMG.
The other parts of Paragraph II reinforce these general
prohibitions.
[[Page 28248]]
Paragraph II.B prohibits the Respondent from facilitating exchanges of
information between health care providers concerning whether, or on
what terms, to contract with a payor. Paragraph II.C bars attempts to
engage in any action prohibited by Paragraph II.A or II.B, and
Paragraph II.D proscribes encouraging, suggesting, advising,
pressuring, inducing, or attempting to induce any person to engage in
any action that would be prohibited by Paragraphs II.A through II.C.
As in other Commission orders addressing health care providers'
collective bargaining with health care payors, certain kinds of
agreements are excluded from the general bar on joint negotiations.
Paragraph II does not preclude ABMG from engaging in conduct that is
reasonably necessary to form or participate in legitimate ``qualified
risk-sharing'' or ``qualified clinically-integrated'' joint
arrangements, as defined in the proposed Consent Order. Also, Paragraph
II would not bar agreements that only involve physicians who are part
of the same medical group practice, defined in Paragraph I.B, because
it is intended to reach agreements between and among independent
competitors.
Paragraphs III through VI require ABMG to notify the Commission
before it initiates certain contacts regarding contracts with payors.
Paragraphs III and IV apply to arrangements under which ABMG would be
acting as a messenger on behalf of its member physicians. Paragraphs V
and VI discuss arrangements under which ABMG plans to achieve financial
or clinical integration.
Paragraph VII.A requires ABMG to send a copy of the Complaint and
Consent Order to its physician members, its management and staff, and
any payors who communicated with ABMG, or with whom ABMG communicated,
with regard to any interest in contracting for physician services, at
any time since January 1, 2001.
Paragraph VII.B requires ABMG to terminate, without penalty, pre-
existing payer contracts that it had entered into since 2001, at the
earlier of (1) receipt by ABMG of a written request for termination by
the payer; or (2) the termination date, renewal date, or anniversary
date of the contract. This provision is intended to eliminate the
effects of ABMG's illegal collective behavior. The payer can delay the
termination for up to one year by making a written request to ABMG.
Paragraph VII.D contains three-year notification provisions
relating to future contact with physicians, payors, management and
staff. This provision requires ABMG to distribute a copy of the
Complaint and Consent Order to each physician who begins participating
in ABMG; each payor who contacts ABMG regarding the provision of
physician services; and each person who becomes an officer, director,
manager, or employee for five years after the date on which the Consent
Order becomes final. In addition, Paragraph VII.D requires ABMG to
publish a copy of the Complaint and Consent Order, annually, in any
official publication that it sends to its participating physicians.
Paragraphs VII.E and VIII-IX impose various obligations on ABMG to
report or to provide access to information to the Commission to
facilitate monitoring its compliance with the Consent Order.
Pursuant to Paragraph X, the proposed Consent Order will expire in
20 years from the date it is issued.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. E9-13956 Filed 6-12-09: 8:45 am]
BILLING CODE: 6750-01-S